About GeneDx AI
GeneDx is a leading provider of advanced genetic testing and genomic sequencing for rare and complex disease diagnosis. The company specializes in whole exome sequencing (ExomeDx™) and whole genome sequencing (GenomeDx™), offering comprehensive analysis across approximately 20,000 genes to help clinicians deliver faster, more accurate diagnoses for patients with suspected genetic conditions. GeneDx has performed over 2.5 million genetic tests, including nearly 1 million exomes and genomes sequenced, creating one of the largest rare disease datasets in the world—GeneDx Infinity™. This dataset, combined with 8 million phenotypic data points, fuels deeper diagnostic insights and enables precision medicine. The company serves multiple stakeholders including healthcare providers, patients and families, health systems, and biopharma companies. GeneDx's testing portfolio addresses a wide range of conditions including neurodevelopmental disorders, epilepsy, autism spectrum disorder, cerebral palsy, congenital heart disease, global developmental delay, intellectual disability, and neonatal/pediatric critical care conditions. The company offers rapid and ultra-rapid testing options, with results available within days or weeks, and accepts simple cheek swabs for most tests with at-home sample collection available. GeneDx is recognized as the #1 genetic test by pediatric and genetic specialists, with diagnostic yield 17% greater than standard testing. The company is an in-network provider for 79% of commercially insured patients across the U.S., with Medicaid coverage available in 36 states, and offers a Financial Assistance Program to reduce out-of-pocket costs. GeneDx integrates with Epic Aura EHR systems and provides comprehensive support including genetic counseling, clearly written reports, and educational resources for clinicians and families.
Mission & Story
Mission
Diagnosis is power. For children with undiagnosed rare diseases, childhood isn't carefree. Answers provide clarity. And clarity provides understanding and hope for brighter tomorrows.
Clinical Focus
Medical conditions and clinical areas addressed by GeneDx AI.
Who It Serves
Milestones & Awards
Recent Milestones
230 new genes linked to autism discovered; AAP recommends exome and genome sequencing for global developmental delay and intellectual disability; over 2.5 million genetic tests performed
Awards & Recognition
Recognized as the #1 genetic test by pediatric and genetic specialists
Key Partnerships
Social & Media
Latest Updates
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.